STE · 10-Q · 2026Q2 · Full report

Headcount / Restructuring

STERIS plc · 2026-08-07 · Importance 46 · Surprise 42 · In source text

STERIS’s May 2024 restructuring plan eliminated approximately 300 positions and included a strategic shift in the European Healthcare surgical business, product rationalizations, and facility consolidations. The plan generated $110.1 million of cumulative pre-tax charges, including $33.9 million in cost of revenues, and had $4.6 million of remaining liability at June 30, 2026 after $2.5 million of payments. On August 5, 2026, the Company announced a new plan to consolidate formulated-chemistry manufacturing and distribution in a North Carolina Center of Excellence. The new plan is expected to close facilities in St. Louis, Missouri, and Plymouth, Minnesota, incur $55 million to $70 million of charges through fiscal 2030, and support Healthcare and Life Sciences formulated-chemistry businesses generating more than $700 million in annual revenue.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
operating_incomenegativecommitted-3.6%The August 5, 2026 restructuring is expected to incur total pre-tax restructuring charges of approximately $55 million to $70 million,…
cashnegativecommitted-0.4%The August 5, 2026 restructuring is expected to incur total pre-tax restructuring charges of approximately $55 million to $70 million,…
assetsnegativecommitted-0.1%The August 5, 2026 restructuring is expected to incur total pre-tax restructuring charges of approximately $55 million to $70 million,…